论文部分内容阅读
癌基因的增宽和出现,可以反映恶性肿瘤的生物学恶性程度,此点首先由神经母细胞瘤的N-myc癌基因的增宽所证实。后来陆续报道,乳癌c-erbB癌基因的出现和c-erbB-2癌基因的增宽与出现,是决定癌术后转归的重要标志。在消化道恶性肿瘤中,食道癌的c-erbB癌基因、胃与结肠腺癌的c-erbB-2癌基因以及食道癌、胃癌的int-2与hst-1癌基因等异常改变,在癌组织中的检出率很高。此类癌基因的异常改变与消化道癌预后的关系,最初是应用测定c-erbB癌基因产物,上皮增生因子受体(EGFR)进行观察的。胃癌EGFR,EGF阳性病例的累积生存率明显低于EGFR、EGF阴性者。食道癌根治术后EGFR高发现组较EGFR僬发现组的累积生存率显著低。c-erbB癌基因
The broadening and appearance of oncogenes can reflect the degree of malignancy of malignant tumors, which was first confirmed by the widening of the N-myc oncogene in neuroblastomas. Later, it was reported in succession that the onset of c-erbB oncogenes and the broadening of c-erbB-2 oncogenes are important markers for the prognosis of cancer. In the digestive tract malignancy, abnormal changes such as c-erbB oncogene in esophageal cancer, c-erbB-2 oncogene in stomach and colon adenocarcinoma, and int-2 and hst-1 oncogene in esophageal cancer and gastric cancer are detected. The detection rate in the organization is high. The relationship between the abnormal changes of these oncogenes and the prognosis of gastrointestinal cancer was initially observed using the c-erbB oncogene product, epidermal growth factor receptor (EGFR). The cumulative survival rate of EGFR and EGF positive cases in gastric cancer was significantly lower than that of EGFR and EGF negative cases. The cumulative survival rate of the EGFR-high discovery group after radical esophageal cancer surgery was significantly lower than that of the EGFR-discovery group. c-erbB oncogene